NRx Pharmaceuticals, Inc. (NRXP)
- Previous Close
3.5600 - Open
3.5400 - Bid 3.4500 x 100
- Ask 3.6900 x 100
- Day's Range
3.5101 - 3.6600 - 52 Week Range
1.9000 - 7.3300 - Volume
40,814 - Avg. Volume
420,610 - Market Cap (intraday)
37.903M - Beta (5Y Monthly) --
- PE Ratio (TTM)
0.68 - EPS (TTM)
5.2000 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.00
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
www.nrxpharma.comRecent News: NRXP
Performance Overview: NRXP
Trailing total returns as of 6/6/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NRXP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRXP
Valuation Measures
Market Cap
38.09M
Enterprise Value
43.55M
Trailing P/E
0.68
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-118.07%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.65M
Diluted EPS (ttm)
5.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
1.32M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.49M
Research Analysis: NRXP
Company Insights: NRXP
NRXP does not have Company Insights